Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia
Journal: Molecular Biology Research Communications (Vol.13, No. 3)Publication Date: 2024.09.01
Authors : Fatima Zohra Moghtit; Wefa Boughrara; Samia Dorgham; Ilies Koriche; Imene Ouahba; Amina Ammour; Amine Bekadja; Meriem Samia Aberkane;
Page : 175-182
Keywords : FLT3; ITD; Acute myeloid leukemia; Prevalence; West of Algeria;
Abstract
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the abnormal and rapid growth of cells. The mutation of the Fms-like tyrosine kinase 3 ligand gene (FLT3-ITD) represents an important factor in the prognosis of AML. The objective of this study was to determine for the first time the prevalence of FLT3-ITD mutation in west Algerian AML patients. A total of 160 AML patients were genotyped for FLT3-ITD mutation by using polymerase chain reaction. FLT3-ITD mutation was detected in 13% of patients. Mutation rates show no significant difference in the distribution of sex and age. A positive association was found between this mutation and a higher leukocyte and blast cells counts. We also found that the M3 and M5 subtype were the commonest in the FLT3 mutated group. This preliminary study provides first-time prevalence estimates for FLT3-ITD mutation in acute myeloid leukemia patients from the West region of Algeria.
Other Latest Articles
- The effects of NLRP3 rs10754558 and rs4612666 polymorphisms on preeclampsia susceptibility, onset, and severity: a case-control study and in silico analysis
- Genome-wide mining and characterization of MATE transporters in Coriandrum sativum L
- Comparison of Mir122 expression in children with biliary atresia and healthy group
- Effects of silymarin as adjuvant drug on serum levels of CTRP3, anti-cyclic citrullinated peptide (CCP), and high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis patients
- Natural compounds solasonine and alisol B23-acetate target GLI3 signaling to block oncogenesis in MED12-altered breast cancer
Last modified: 2024-07-02 16:49:48